Dr. David A. Marks, M.D.

Medicare patients and services

Medicare patients, 2024

1,124

Services billed

4,699

Patients’ average age

76

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 23 companies reported 202 payments worth $107,052 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 13 industry-funded studies in 2025, from 9 companies. The companies reported $140,115 in research payments for these studies, mostly to the institutions running them.

• A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
  AstraZeneca Pharmaceuticals LP
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  Sanofi US Services Inc. · Recruiting · NCT07190209
• A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
  Verona Pharma, Inc.
• -Ph III (52w+ in NCFBE +/- CFBE)
  Boehringer Ingelheim Pharmaceuticals, Inc.
• A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIR…
  Boehringer Ingelheim International GmbH
• A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
  Teva Pharmaceuticals USA, Inc.
• A 52-week, randomised, double-blind, double-dummy, parallel group, mul
  GlaxoSmithKline, LLC.
• A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Rel…
  AstraZeneca Pharmaceuticals LP
• A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulm…
  AstraZeneca Pharmaceuticals LP
• A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma
  AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pulmonology clinicians in San Antonio

• Mohamed Abdalla, MD
• Ali Abedi, M.D.
• Sandra Adams, MD
• Bravein Amalakuhan, M.D.
• Liwayway R. Andrade, M.D.
• Charles P. Andrews, M.D.
• Antonio Anzueto, MD
• Aristides J. Armas Villalba, MD